Ticker

Analyst Price Targets — TNYA

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
March 12, 2026 2:37 pmMani ForooharLeerink Partners$2.00$0.95StreetInsider Leerink Partners Reiterates Outperform Rating on Tenaya Therapeutics Inc (TNYA): "remains on track to share interim data"
January 8, 2026 12:44 pmMorgan Stanley$2.00$0.80TheFly Tenaya Therapeutics price target lowered to $2 from $5 at Morgan Stanley
December 12, 2025 1:47 pmH.C. Wainwright$3.00$0.88TheFly Tenaya Therapeutics price target lowered to $3 from $5 at H.C. Wainwright

Latest News for TNYA

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief…

Globe News Wire • Jul 14, 2026
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief…

GlobeNewsWire • Jul 14, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for TNYA.

No House trades found for TNYA.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top